CANNABIS is finally going mainstream with news the Therapeutic Goods Association lowered the poisons standard to allow CBD products to be sold in pharmacies across the nation.
Althea Group Holdings Limited informed investors via the Australian Stock Exchange today announcing the regulatory change would allow CBD products to be sold over-the-counter from February 1.
“Australian medicinal cannabis company Althea Group Holdings Limited (ASX: AGH) (‘Althea’ or ‘the Company’) is delighted to announce that a major regulatory change has been confirmed in relation to the status of cannabidiol CBD in Australia,” Althea Group announced.
Althea CEO Josh Fegan said the move by the Therapeutic Goods Association (TGA) was great news for the industry and customers.
“Althea applauds the final decision by the TGA to amend the current Poisons Standard to down schedule CBD to allow greater access through a new Schedule 3 entry 1,” Mr Fegan said.
“The amendment will allow Australian patients to purchase CBD products upon consultation with a pharmacist, without the need for a prescription.
“Althea will now proceed with plans to register several CBD products for sale in Schedule 3, including the top selling Althea CBD100.”
The move allows CBD products to be classified as a Schedule 3 poison, permitting sale once all requirements are met.
“We applaud the TGA’s final…
